CTIS2022-503091-89-00招募中1 期
A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function (Varvara) - ARGX-117-2201
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Argenx
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Is at least the local legal age of consent for clinical studies and at least aged 18 years and less than 70 years when signing the ICF, Have received SARS-CoV-2 vaccinations consistent with participating site’s requirements, Is capable of providing signed informed consent and complying with protocol requirements, Agree to use contraceptive measures consistent with local regulations, Have dry body weight less than 120 kg and body mass index less than 40 kg/m2 at screening, Are diagnosed with ESRD and have been stable on chronic dialysis for at least 3 months, Are recipients of de novo or second-time, single kidney transplant from a deceased donor, either DCD or DBD, Are ABO compatible with donor allograft, except for type A2 donor to type B recipient kidneys, Have a negative cross match, Have received pretransplant vaccinations for: Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae, or are willing to receive the vaccinations approximately 3 to 4 months posttransplant
排除标准
- •Any history of prothrombotic disorder, or history of thrombosis or hypercoagulable state, excluding vascular access clotting, Clinically significant active bacterial, viral, or fungal infection or infection with HBV, HCV, HIV or tuberculosis, Clinically significant comorbidity, recent major surgery (within 3 months of screening), history of any treatment nonadherence, or intention to have surgery during the study other than kidney transplantation; or any other medical condition that, in the investigator’s opinion, would confound the results of the study or put the participant at undue risk, Received a different IMP in another clinical study less than 12 weeks or 5 half-lives (whichever is longer) before screening, Currently participating in another interventional clinical study, Previously participated in an ARGX-117 clinical study and received at least 1 dose of IMP, Known hypersensitivity to ARGX-117 or any of its excipients, Known hypersensitivity to tacrolimus, MMF or mycophenolic acid, or antithymocyte globulin or allergy to Leporidae (eg, rabbit), History (within 12 months before screening) of current alcohol, drug, or medication abuse as assessed by the investigator, Pregnant or lactating state or intention to become pregnant during the study, Received any prior desensitization therapies or any pretransplant immunosuppressive therapy within 5 half-lives or twice the duration of the biological effect, whichever is longer., Any known history of complement deficiency, Evidence of peritonitis in participants on peritoneal dialysis, Received any solid organ, bone marrow, or hematopoietic stem cell transplant, with the exception of prior first kidney transplant, High risk within the study period for recurrence of underlying renal disease in the opinion of the investigator, Current treatment for an autoimmune disease requiring maintenance immunosuppression to control systemic disease activity that would pose a significant safety risk or put the participant at undue harm in the opinion of the investigator, Any history of clinically significant arrythmia, known long QT syndrome, or clinically significant ECG abnormality at screening, including QTcF >450 ms for male participants and QTcF >470ms for female participants, Any history of malignancy unless considered cured by adequate treatment with no evidence of recurrence for more than 5 years before the first administration of IMP. Adequately treated participants with the following cancers can be included at any time: a. Basal cell or squamous cell skin cancer; b. Carcinoma in situ of the cervix; c. Carcinoma in situ of the breast; d. Incidental histological finding of prostate cancer, Unwillingness to receive vaccinations consistent with protocol-mandated and participating site requirements
研究者
相似试验
尚未招募
2 期
A Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerCancerPACTR202404480503746Hoffmann La Roche160
尚未招募
2 期
A Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer_CancerPACTR202405736542144Hoffmann La Roche160
进行中（未招募）
不适用
A Phase Two, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia - Pivotal Asia Efficacy StudyTravelers DiarrheaMedDRA version: 12.0Level: LLTClassification code 10044552Term: Traveller's diarrheaEUCTR2009-015603-10-GBIntercell USA, Inc716
进行中（未招募）
不适用
A Phase Two, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia - Pivotal Asia Efficacy StudyTravelers DiarrheaMedDRA version: 12.0Level: LLTClassification code 10044552Term: Traveller's diarrheaEUCTR2009-015603-10-DEIntercell USA, Inc716
进行中（未招募）
1 期
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's SyndromeEUCTR2016-000101-37-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO120